Unraveling FcepsilonRI-independent regulation of mast cell functions by the ITCH ubiquitin ligase
- Institution
- University of South Carolina at Columbia, SC
- Principal investigator
- Carole A Oskeritzian
- Funding
- $224K
- Duration
- 2025–2027
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY Mast cells (MC) are innate immune cells that occupy a unique niche in tissues in which they reside as long-lived perpetrators of immunoglobulin E (IgE)-mediated hypersensitivity and many other inflammatory responses. We have shown that MC initiate skin and lung inflammation through the rapid release of inflammatory mediators, including cell-attracting chemokines. This occurs, in part, in a FcεRI-independent manner through ligation of receptors (R) for a bioactive signaling lipid, sphingosine-1-phosphate (S1P), and for lipopolysaccharide (LPS), an endotoxin present in most environmental antigens (Ag) penetrating the body. Engagement of MC-stimulating R signalosomes encompasses kinase phosphorylation/activation, ultimately leading to transcription factor signal transducer and activator of transcription 3 (STAT3) and nuclear factor kappa light chain enhancer of activated B cells (NF-κB) activation, linked to chemokine release. Little is known about the regulatory pathways halting MC activation to restore homeostasis. One of the mechanisms limiting inflammation and MC functions is through ubiquitination. E3 ubiquitin ligases attach ubiquitin chains to protein substrates for rapid removal of unwanted or damaged proteins and have been described as negative regulators of IgE-mediated signaling and subsequent mediator release by MC. Deficiency of the E3 ubiquitin ligase ITCH results in systemic inflammation of the mucosal surfaces, such as skin and lungs. Similar findings are described in human patients, including clinical manifestations of atopy. Thus, there is an unmet need to understand how ITCH regulates inflammation and MC biology. Our preliminary data show that primary MC express ITCH, which is predicted to interact with several MC-restricted enzymes. Moreover, ITCH negatively regulates inflammation by controlling the ubiquitin-editing enzyme TNF Alpha Induced Protein 3 (Tnfaip3/A20) function, thus NF-κB activation. ITCH is also predicted to interact with Bruton’s tyrosine kinase (BTK), an enzyme involved in MC activation that we also found is essential to STAT3 activation downstream of S1P signaling in MC (our preliminary data). The objectives of this application are to determine how ITCH affects MC intrinsic function in vitro and in vivo, and to identify ITCH-regulated targets in these pathways using primary MC. We anticipate that our proposed studies will provide novel mechanistic data delineating how ITCH, an E3 ubiquitin ligase, can regulate signaling mechanisms driving skin and lung inflammation and MC functions. These mechanistic insights will identify an actionable inflammation-enabling molecular target in ITCH as a regulator of MC reactivity, with the potential to prevent the onset of inflammation and progress to a diseased state.
Research team
- Lydia Eleanor MatesicPI
- Carole A OskeritzianPI
LOADING MOONBASE SCORE
Questions for University of South Carolina at Columbia
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · University of South Carolina at Columbia66
Using Open-Source Technology to Measure Energy Expenditure and Sleep Among Children 3 to 8 Years Old
Bridget R. Armstrong · $722K · 2023–2028
- NSF · University of South Carolina at Columbia58
EAGER: NAIRR Pilot: Demonstrating a Compact Foundation Model for Planning-Like(PL) Tasks for Next Generation Trusted Applications
Biplav Srivastava · $300K · 2025–2027
- NSF · University of South Carolina at Columbia56
CAS: Dual-Site Relay Catalysis in Oxygen Reduction Reactions on Reducible Metal Oxide Heterojunction Structures
Zhenmeng Peng · $351K · 2023–2024